Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Twice daily
MoneyWeek
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Four times a week
Look After My Bills
Sign up to our free money-saving newsletter, filled with the latest news and expert advice to help you find the best tips and deals for managing your bills. Start saving today!
Dechra Pharmaceutical's Group Finance Director, Simon Evans, has quit suddenly after 15 years in the job, and won't be sticking around to work with his successor.
In a brief statement the veterinary pharmaceuticals company said: "Simon recognises that following the acquisitions of Eurovet and Vetxx, and their successful integration within the group, it is now time for the company to recruit a new Finance Director with the relevant skills, energy and experience to take the group to its next strategic level. The board has therefore agreed to accept his resignation and that he should leave the board and the company with immediate effect."
While animal pharmaceuticals and veterinary drugs company Dechra searches for a successor, the Group Finance Director role will be fulfilled by Simon's deputy, the Group Financial Controller, Paul Sandland.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The news accompanied a solid interim management statement for the period from July 1st to 19th October, with trading in line with management expectations. Revenue growth in the first quarter was 21.9% ahead of the same period last year (24.9% at constant currency). Excluding Eurovet, the increase was 6% (8.9%) at constant currency).
The best performance was from its US Pharmaceuticals operation, where revenues were 24.8% higher than the first quarter last year (21.9% at constant currency).
CM
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
UK interest rates live: experts expect MPC to hold ratesThe Bank of England’s Monetary Policy Committee (MPC) meets today to decide UK interest rates. The last meeting resulted in a cut, but experts think there is little chance of interest rates falling today.
-
MoneyWeek Talks: The funds to choose in 2026Podcast Fidelity's Tom Stevenson reveals his top three funds for 2026 for your ISA or self-invested personal pension
